Andrew Walker and Dinkar Juyal are Machine Learning Engineers at PathAI.

AI pathology specialist PathAI has announced a multi-year expanded collaboration agreement with Bristol Myers Squibb. The initial work within this extended agreement will focus on key translational research in oncology, fibrosis, and immunology, with an overall goal to forward these into clinical trials. PathAI develops quantitative pathology algorithms for drug discovery and development. "We look forward to collaborating with PathAI to expand the potential application of AI in the drug development process to include translational research, clinical trials, and diagnostic advancements," said Robert Plenge, MD, PhD, senior vice president of Bristol Myers Squibb, head of Immunology, Cardiovascular, and Fibrosis Thematic Research Center, and head of Translational Medicine. "We feel that PathAI will be a productive collaborator given digital pathology represents a growing area for BMS, PathAI is a leader in the field, and the fact that we have a long-standing productive relationship with the company," he added.

Today Roche announced a new collaboration with Bristol Myers Squibb that will use cutting edge digital methods to improve standardization and interpretation of tissue-based assays and will leverage Roche's established partnership with PathAI. Roche plans to integrate a novel PathAI-developed algorithm for biomarker analysis into their digital pathology workflow software. The AI-powered algorithm will be used to analyze clinical trial samples and generate biomarker data. These imaging tools will enable very precise diagnoses that will lead to personalized treatment options for patients with solid tumors. In October 2021, Roche announced a strategic partnership with PathAI.

Today Roche announced a new collaboration with Bristol Myers Squibb that will use cutting edge digital methods to bring significant improvements in standardization and interpretation of tissue-based assays. This new partnership will leverage Roche's established partnership with PathAI. Through this new collaboration, Roche will integrate a novel PathAI-developed algorithm for biomarker analysis into their digital pathology workflow software. The AI-powered algorithm will be used by Bristol Myers Squibb to analyze clinical trial samples and generate biomarker data. These pathology imaging tools will enable very precise diagnoses that will lead to personalized treatment options for patients with solid tumors.

"Our commitment is to provide the best possible care for our patients, and it is increasingly clear that AI-powered pathology can radically enhance diagnostic accuracy and treatment selection." PathAI and Cleveland Clinic have announced a 5 year strategic collaboration. The partnership will combine PathAI's AI-based platforms with Cleveland Clinic's clinical expertise and multi-modal data to unlock a broad implementation of next-generation pathology diagnostics. The objective is to accelerate innovation in precision pathology and to bridge communities in the healthcare ecosystem including patients, biopharma, and academic research. Cleveland Clinic will leverage PathAI's quantitative pathology algorithms to conduct new translational research and for use as clinical diagnostics in multiple disease areas.

In the digital world, top AI companies in social good are coming up with innovative AI solutions to address worldly challenges. Artificial intelligence for social good is making significant impacts in diverse industries.

Every day, in our web blog page, I've been stating that Artificial Intelligence and Machine Learning are gaining important traction within the business, with companies increasingly using these modern technologies to enhance business operations and better tailor customer preferences. Today, I would like to provide you some use cases of AI by giving major 15 brands as examples that adopted AI to improve their business operations and growth. Before that, let's look into the below AI statistics to know how beneficial brands can be in pleasing their customers. Undoubtedly, Amazon is the big brand that has adopted AI at first and highly benefited from this trending technology. Let me explain one of the best use cases of Artificial intelligence.

Paul Matthews, freelance tech writer, writes about examples of machine learning across the the healthcare, entertainment, marketing and education industries. From front end development to the automotive sector, the applications of machine learning for business purposes is bigger than ever. Examples of machine learning in the real world include recommendation engines, object detection, natural language processing, and more. Let's analyse five interesting examples of how ML is being used to deliver better online experiences and advance healthcare and education. Companies like Universal, Sony and EMI have gone through a massive digitalization in the past 10 years, evolving from "selling a certain number of records" to "streaming that record for'n' number of times". Monetization via ads through plays on portals like Youtube, Spotify and Soundcloud is something sought after.

Artificial Intelligence (AI) is taking over every industry. We've had electricity, we've had the internet, and now, we have AI. The goal of artificial intelligence is to simulate human intelligence using computers. Humans (at least so far) are a lot smarter than computers. We can solve complex problems such as building bridges.

PathAI, a leading provider of AI-powered technology for advancing pathology research, announced that it has appointed translational medicine and digital pathology leader, Michael C. Montalto, PhD, as Chief Science Officer. Dr. Montalto joins PathAI from Bristol-Myers Squibb (BMS), where he was Vice President and Head of Translational Sciences, Translational Medicine. "We are incredibly fortunate and excited to welcome Mike onto our leadership team," said Andrew Beck, MD, PhD, co-founder and Chief Executive Officer of PathAI. "Mike brings tremendous experience developing digital pathology diagnostic products and driving cutting-edge translational research in a large biopharmaceutical setting. We are thrilled to be working with Mike at PathAI to use AI-powered pathology to support the development of new therapies and diagnostics for patients."